Nuzenio

Plus Ivonescimab

Plus Ivonescimab news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Akeso Doses First Patient in Phase II Trial of Dual-Targeting ADC Plus Ivonescimab for Advanced Breast Cancer - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 18:43:00 GMTAkeso Doses First Patient in Phase 2 Trial of Bispecific ADC AK146D1 Plus Ivonescimab in Breast Cancer - BioPharm InternationalBioPharm International · Mon, 10 Aug 2026 16:47:15 GMTDevelopers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 16:04:44 GMT

Timeline

Mon, 10 Aug 2026 18:43:00 GMTAkeso Doses First Patient in Phase II Trial of Dual-Targeting ADC Plus Ivonescimab for Advanced Breast Cancer - finance.biggo.com
Mon, 10 Aug 2026 16:47:15 GMTAkeso Doses First Patient in Phase 2 Trial of Bispecific ADC AK146D1 Plus Ivonescimab in Breast Cancer - BioPharm International
Thu, 06 Aug 2026 16:04:44 GMTDevelopers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer - CancerNetwork

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Plus Ivonescimab.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.